CD47 and anemia (phenotype): A priming dosage of the SIRPα-CD47 blocker or choosing the Fc domain of the anti-CD47 mAb to limit interactions with the phagocyte Fc receptor are currently being tried as strategies to reduce RBC phagocytosis and the associated anemia [13,109,112,113].